Formalin-fixed paraffin embedded (FFPE) tumor tissue provides an opportunity to perform retrospective genomic studies of tumors in which chromosomal imbalances are strongly associated with oncogenesis. The application of comparative genomic hybridization (CGH) has led to the rapid accumulation of cytogenetic information on osteosarcoma (OS); however, the limited resolving power of metaphase CGH does not permit precise mapping of imbalances. Array CGH allows quantitative detection and more precise delineation of copy number aberrations in tumors. Unfortunately the high cost and lower density of BACs on available commercial arrays has limited the ability to comprehensively profile copy number changes in tumors such as OS that are recurrently subject to genomic imbalance. In this study a cDNA/EST microarray including 18,980 human cDNAs (which represent all 22 pairs of autosomal chromosomes and chromosome X) was used for CGH analysis of eight OS FFPE. Chromosomes 1, 12, 17, and X harbored the most imbalances. Gain/amplification of X was observed in 4/8 OS, and in keeping with other recent genomic analyses of OS, gain/amplification of 17p11.2 was often accompanied by a distal deletion in the region of the p53 gene. Gain/amplification of the X chromosome was verified using interphase FISH carried out on a subset of OS FFPE sections and OS tissue arrays.    

1.
Alcock HE, Stephenson TJ, Royds JA, Hammond DW: Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization. Genes Chrom Cancer 37:369–380 (2003).
2.
Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K, Bridge JA, Soresen P, Thorner P, Squire JA: Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17 and 20 in osteosarcoma. Genes Chrom Cancer 36:7–16 (2003).
3.
Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire J: Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 5:53–62 (2003).
4.
Brinkschmidt C, Blasius S, Burger H, Simon R, Diallo R, Battmann A, Winklemann W, Bocker W, Dockhorn-Dworniczak B: Comparative genomic hybridization (CGH) for detecting a heretofore undescribed amplified chromosomal segment in high-grade medullary osteosarcoma. Verh Dtsch Ges Pathol 82:184–188 (1998).
5.
El-Rifai W, Sarlomo-Rikala M, Knuutila S, Miettinen M: DNA copy number changes in development and progression in leiomyosarcomas of soft tissues. Am J Pathol 153:985–990 (1998).
6.
Elsea SH, Mykytyn K, Ferrell K, Coulter KL, Das P, Dubiel W, Patel PI, Metherall JE: Hemizygosity for the COP9 signalosome subunit gene SGN3 in the Smith-Magenis syndrome. Am J Med Genet 87:342–348 (1999).
7.
Fazeny-Dorner B, Piribauer M, Wenzel C, Fakhrai N, Pirker C, Berger W, Sedivy R, Rudas M, Filipits M, Okamoto I, Marosi C: Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy. Cancer Genet Cytogenet 146:161–166 (2003).
8.
Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, Geurts van Kessel A: Comparative genomic hybridization analysis of human sarcomas. II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chrom Cancer 14:15–21 (1995).
9.
Forus A, Berner JM, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad O, Myklebost O: Molecular characterization of a novel amplicon at 1q21→q22 frequently observed in human sarcomas. Br J Cancer 78:495–503 (1998).
10.
Henegariu O, Heerema NA, Thurston V, Jung S, Pera M, Vance G: Characterization of gains, losses and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. Cancer Genet Cytogenet 148:14–20 (2004).
11.
Henriksen J, Aagesen T, Maelandsmo G, Lothe R, Myklebost O, Forus A: Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22:5358–5361 (2003).
12.
Jorn H, Trude AH, Gunhild MM, Ragnhild LA, Ola M, Forus A: Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22:5358–5361 (2003).
13.
Larramendy M, Tarkkanen M, Blomqvist C, Virolainen M, Wiklund T, Asko-Seljavaara S, Elomaa I, Knuutila S: Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol 151:1153–1161 (1997a).
14.
Larramendy M, Tarkkanen M, Valle J, Kivioja A, Ervasti H, Karaharju E, Salmivalli T, Elomaa I, Knuutila S: Gains, losses and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 150:685–691 (1997b).
15.
Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chinttagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R, Rai PH: Frequent amplification and rearrangment of chromosomal bands 6p12→p21 and 17p11.2 in osteosarcoma. Genes Chrom Cancer 39:11–21 (2004).
16.
Lopez-Gines C, Carda-Batalla C, Lopez-Terrada L, Llombart-Bosch A: Presence of double minutes and monosomy 17p in xenografted human osteosarcomas. Cancer Genet Cytogenet 90:57–62 (1996).
17.
Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP: Genomic microarrays in the spotlight. Trends Genet 20:87–94 (2004).
18.
Mertens F, Larramendy M, Gustavosson A, Gisselsson D, Rydholm A, Brosjo O, Mitelman F, Knuutila S, Mandahl N: Radiation-associated sarcomas are characterized by complex karyotypes with frequent rearrangements of chromosome arm 3p. Cancer Genet Cytogenet 116:89–96 (2000).
19.
Ozaki T, Schaefer KL, Wai D, Buerger H, Flege S, Lindner N, Kevric M, Diallo R, Bankfalvi A: Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 102:355–365 (2002).
20.
Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41–46 (1999).
21.
Sandberg AA, Bridge J: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 145:1–30 (2003).
22.
Simon R, Mirlacher M, Sauter G: Tissue microarrays. Biotechniques 36:98–105 (2004).
23.
Squire J, Marrano P, Kolomietz E: FISH: A Practical Approach. (Oxford University Press, Oxford 2002).
24.
Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, Zielenska M: High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chrom Cancer 38:215–225 (2003).
25.
Stock C, Kager L, Fink FM, Gadner H, Ambros PF: Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chrom Cancer 28:329–336 (2000).
26.
Szymanska J, Mandahl N, Mertens F, Tarkkanen M, Karaharju E, Knuutila S: Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13→q15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 16:31–34 (1996).
27.
Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Bohling T, Karaharju E, Hyytinen E, Knuutila S, et al: Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 55:1334–1338 (1995).
28.
Tarkkanen M, Bohling T, Gamberi G, Ragazzini P, Benassi MS, Kivioja A, Kallio P, Elomaa I, Picci P, Knuutila S: Comparative genomic hybridization of low-grade central osteosarcoma. Mod Pathol 11:421–426 (1998).
29.
Tarkkanen M, Elomaa I, Blomqvist C, Kivioja A, Kellokumpu-Lehtinen P, Bohling T, Valle J, Knuutila S: DNA sequence copy number increase at 8q: a potential new pronostic marker in high-grade osteosarcoma. Int J Cancer 84:114–121 (1999).
30.
Terracciano LM, Bernasconi B, Ruck P, Stallmach T, Briner J, Sauter G, Moch H, Vecchione R, Pollice L, Pettinato G, Gurtl B, Ratschek M, De Krijger R, Tornillo L, Bruder E: Comparative genomic hybridization analysis of hepatoblastoma reveals high frequency of X-chromosome gains and similarities between epithelial and stromal components. Hum Pathol 34:864–871 (2003).
31.
van Dartel M, Cornelissen PW, Redeker S, Tarkkanen M, Knuutila S, Hogendoorn PC, Westerveld A, Gomes I, Bras J, Hulsebos TJ: Amplification of 17p11.2 approximately p12 including PMP22 TOP3A and MAPK7 in high-grade osteosarcoma. Cancer Genet Cytogenet 139:91–96 (2002).
32.
Wei G, Lonardo F, Ueda T, Kim T, Huvos A, Healey J, Ladanyi M: CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 80:199–204 (1999).
33.
Wolf M, Tarkkanen M, Hulsebos TJ, Larramendy M, Forus A, Myklebost O, Aaltonen LA, Elomaa I, Knuutila S: Characterization of the 17p amplicon in human sarcomas: microsatellite marker analysis. Int J Cancer 82:329–333 (1999).
34.
Zielenska M, Bayani J, Pandita A, Toledo S, Marrano P, Andrade J, Petrilli A, Thorner P, Sorensen PHB, Squire JA: Comparative genomic hybridization analysis identifies gains of 1p35→36 and chromosome 19. Cancer Genet Cytogenet 130:14–21 (2001).
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.